Paradigm Biopharmaceuticals has selected Advanced Clinical as the clinical research organisation (CRO) to support its pivotal ...

Paradigm Biopharmaceuticals continues to edge closer towards starting the pivotal phase III trial for its knee osteoarthritis ...

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its ...

PhaseV has formed a strategic collaboration with Alimentiv for supporting the design and execution of adaptive clinical ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from ...

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...

GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Garty, chief technology officer, clinical data, provided his key takeaways from a panel he participated in on the growing interest ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

The research offers hope to tens of thousands of patients with kidney failure who are on a long waiting list for an organ ...